There is much excitement in the world of AI and healthcare. From the promise of mass analysis and management of patient health records, to advanced predictive diagnosis methods, it’s easy to be optimistic about the future of healthcare when you consider the potential power of well-distributed, ethically robust and technically advanced AI systems. And with the AI market looking to grow at an annual rate of 40% through to 2021, reaching $6.6 billion that year as opposed to only $600 million in 2014, the business opportunity in field is attracting a new wave of entrepreneurs, clinicians and scientists adopting AI systems into the heart of their healthcare innovations.

CREATING A FUTURE WHERE AI WILL TRANSFORM HEALTH
THE WORLD'S LARGEST SUMMIT DEDICATED TO AI IN MEDICINE PARTNERS WITH THE NOVARTIS FOUNDATION AND NHSX TO REVOLUTIONISE AI IN MEDICINE IN LINE WITH THE UNITED NATIONS SUSTAINABLE DEVELOPMENT GOALS

Brought to you by InspiredMinds, the team behind World Summit AI (where the global AI agenda is set annually), Intelligent Health 2019 will host over 2,000 attendees, bring together 100 of the brightest brains in healthcare and tech to take centre stage, and aims to create a future where AI revolutionises healthcare.

You can have a sneak peek at the first 60 ground-breaking speakers confirmed so far, find out more about this inspiring event on our website and watch the 2018 aftermovie to get a taste of what's coming.

By Christopher Rudolf, Founder and CEO at Volv Global

Quantifying Predictive Power of Features in Electronic Health Record Models – the Volv inTrigue way

In 8 weeks’ time, Intelligent Health (11th-12th September), the world’s largest CPD accredited summit dedicated to AI in healthcare is descending on Basel, Switzerland.

To give you a taster of what's to come, meet Mr Roland Rott, Global GM of Women’s Health Ultrasound for GE Healthcare who joins our 2019 line up!

By Christopher Rudolf, Founder and CEO at Volv Global

The Case Study Problem

This case study derives from an ongoing Volv engagement, which started in July 2017. A pharmaceutical company approached Volv Global to develop a prediction model to identify additional patients suffering from the rare disease treatable by its specialist medicine.

By Christopher Rudolf, Founder and CEO at Volv Global

Redefining your strategy using machine learning with Volv inTrigue

In this series of conversations with Volv leaders, I have been talking with Dr Mike Tremblay, Volv’s Chief Scientific and Medical Officer, about what differentiates the company in terms of value delivery into markets for our customers. I hope that this is of interest to those of you working with difficult to diagnose diseases and rare diseases in your daily activities.